Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

CompletedOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 31, 2024

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

DRUG

inetetamab

8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days

Trial Locations (1)

Liaoning Cancer Hospital &Institue, Shenyang

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER